Novo has reduced the price of Norditropin FlexPro, a growth hormone medicine, by up to 35% in India. According to an ET Pharma report published on 15 October 2026, the price of the 10 mg device has fallen from ₹16,836 to ₹11,300, while the 15 mg device price has decreased from ₹25,254 to ₹16,450. The revised prices may improve affordability for patients requiring growth hormone therapy.
Quick Summary
Novo has reduced Norditropin FlexPro prices in India by up to 35%. The 10 mg device is now priced at ₹11,300, compared with ₹16,836 previously. The 15 mg device costs ₹16,450, down from ₹25,254. The price revision comes amid competition in India’s growth hormone therapy market.
Norditropin FlexPro Price Reduction in India: Overview
Norditropin FlexPro contains somatropin, a laboratory-produced form of human growth hormone. The reported price reduction applies to its 10 mg and 15 mg devices in India.
| Particulars | Details |
|---|---|
| Company | Novo (formerly Novo Nordisk) |
| Brand Name | Norditropin FlexPro |
| Active Ingredient | Somatropin |
| Product Category | Growth hormone therapy |
| Market | India |
| Maximum Reported Price Reduction | 35% |
| 10 mg Revised Price | ₹11,300 |
| 15 mg Revised Price | ₹16,450 |
| News Report Date | 15 October 2026 |
| Source of Report | ET Pharma |
Norditropin FlexPro New Price in India: 10 mg and 15 mg
According to the report, Novo has revised the prices of two Norditropin FlexPro device strengths. The updated prices are shown below.
| Device Strength | Previous Price | New Price | Reported Reduction | Price Difference |
|---|---|---|---|---|
| 10 mg | ₹16,836 | ₹11,300 | 33% | ₹5,536 |
| 15 mg | ₹25,254 | ₹16,450 | 35% | ₹8,804 |
The 10 mg device has become ₹5,536 cheaper, while the 15 mg device has decreased in price by ₹8,804, based on the reported figures.
Patients should confirm the latest price and availability with an authorised pharmacy or healthcare provider before purchasing.
What Is Norditropin FlexPro?
Norditropin FlexPro is a growth hormone medicine containing somatropin, a recombinant form of human growth hormone.
Growth hormone plays an important role in normal growth and development. Somatropin medicines may be prescribed for growth hormone deficiency and other approved conditions, depending on the product’s approved indications and the patient’s clinical assessment.
Norditropin FlexPro is a prescription medicine and should be used under appropriate medical supervision. The dosage and duration of treatment depend on the patient’s diagnosis, age, clinical condition and response to treatment.
Why Has Novo Reduced Norditropin FlexPro Prices?
The ET Pharma report published on 15 October 2026 describes the price revision in the context of affordability and competition in India’s growth hormone therapy market.
Domestic pharmaceutical companies, including Reliance Life Sciences, Sun Pharma and Cipla, are mentioned in the report as competitors in this market.
Several factors may influence pricing decisions in specialised medicine segments:
- Affordability: Lower device prices may reduce the purchase cost for patients.
- Market competition: Companies may revise prices in response to competing products.
- Market access: Pricing can influence the ability of patients to access specialised therapies.
- Commercial strategy: Companies may adjust prices to remain competitive.
The exact contribution of each factor to this particular price revision has not been quantified in the information provided.
How Will the Norditropin Price Cut Affect Patients?
The price reduction may help patients who have been prescribed Norditropin FlexPro and purchase the affected devices at the revised prices.
1. Lower Purchase Cost
The reported prices of both the 10 mg and 15 mg devices have decreased. This may reduce the amount patients pay for these devices.
2. Potential Improvement in Affordability
A lower medicine price may make treatment more affordable for some patients. However, the overall financial impact will depend on the prescribed regimen and other treatment-related expenses.
3. Better Price Comparison
Patients and caregivers can use the revised prices to compare current costs when discussing treatment options with their healthcare providers.
4. Greater Competition in the Growth Hormone Market
The price revision highlights the competitive environment in India’s specialised growth hormone therapy segment.
Important: The reported device price reduction does not necessarily mean that total treatment expenditure will decrease by the same percentage. Consultations, diagnostic tests and ongoing monitoring may also contribute to treatment costs.
Patients should not change their dosage, discontinue treatment or switch medicines solely because of a price change. Any treatment modification should be discussed with the treating specialist.
Impact on India’s Pharmaceutical Industry
Novo’s Norditropin FlexPro price revision is a notable development in India’s growth hormone therapy market.
Competition among pharmaceutical companies can influence pricing strategies, product positioning and access to specialised medicines. Price adjustments may be one way companies respond to changing market conditions.
However, the long-term effect of this price revision on market share, prescribing patterns and patient access remains uncertain. Further market information would be needed to establish these outcomes.
For pharmaceutical professionals and students, this development illustrates the role of pricing strategy and competition in the pharmaceutical industry.
Frequently Asked Questions (FAQs)
1. What is the new price of Norditropin FlexPro in India?
According to the ET Pharma report published on 15 October 2026, the revised price is ₹11,300 for the 10 mg device and ₹16,450 for the 15 mg device.
2. How much has the Norditropin FlexPro 10 mg price decreased?
The 10 mg device price has decreased from ₹16,836 to ₹11,300, a reduction of ₹5,536. The reported percentage reduction is 33%.
3. What is the price reduction for Norditropin FlexPro 15 mg?
The 15 mg device price has decreased from ₹25,254 to ₹16,450. This represents a price difference of ₹8,804, with a reported reduction of 35%.
4. What is the active ingredient in Norditropin FlexPro?
Norditropin FlexPro contains somatropin, a recombinant form of human growth hormone.
5. What is Norditropin FlexPro used for?
Norditropin FlexPro is a prescription growth hormone medicine used for approved indications, including growth hormone deficiency, subject to the applicable product label and medical assessment.
6. Why has Novo reduced Norditropin FlexPro prices?
The ET Pharma report discusses affordability and competition in India’s growth hormone therapy market in connection with the price revision. The exact contribution of individual factors has not been quantified in the information provided.
7. Does the price reduction mean that the total cost of growth hormone treatment will decrease by 35%?
No. The reported reduction applies to the listed prices of the specified devices. Total treatment expenditure may also include consultations, diagnostic tests, monitoring and other healthcare expenses.
8. Should patients change their growth hormone treatment after the price reduction?
No treatment change should be made solely because of a price reduction. Patients should consult their treating specialist before changing their medicine, dosage or treatment plan.
Conclusion
Novo has reduced the reported prices of Norditropin FlexPro devices in India by up to 35%. The 10 mg device is now listed at ₹11,300, while the 15 mg device is listed at ₹16,450, according to the ET Pharma report dated 15 October 2026.
The price revision may improve affordability for patients requiring prescribed growth hormone therapy. However, patients should confirm current prices and availability before purchasing and continue to follow their healthcare provider’s advice.
For pharmaceutical students and professionals, this development also highlights the importance of medicine pricing, market competition and patient access in India’s pharmaceutical industry.
Recommended Products
